Aldara
designed to target viral or abnormal cell lesions and to alleviate site-specific skin conditions.
Strengths: 5%
Where to Check Availability
Medicine details
- Alternative names
Zyclara
- Therapeutic class
Immunomodulator
- Pharmacological class
Imidazoquinoline
- Contraindications
hypersensitivity to imiquimod
- Minor side effects
erythema; excoriation; scaling; oedema
- Moderate side effects
erosion; ulceration; application site pain
- Serious side effects
severe inflammatory reaction — requires immediate medical attention
- Dosage forms
Cream
- Administration route
Cutaneous use
- Prescription status
POM
- Manufacturer
Viatris
- Onset Time
4–8 weeks
- Duration
as prescribed
- Storage instructions
Do not freeze; store below 25°C.
- Age restrictions
Not for children unless specified.
- Pregnancy and breastfeeding
Pregnancy: Consult doctor prior to use. Breastfeeding: Use with caution.
Precautions and warnings
avoid contact with eyes and mucous membranes; limit exposure to sunlight; do not apply to broken skin
Patient summary
designed to target viral or abnormal cell lesions and to alleviate site-specific skin conditions.
Mechanism of action
Functions as an immune response modifier, inducing the production of interferon-alpha and other cytokines to localise immune activity at the application site.
Aldara
designed to target viral or abnormal cell lesions and to alleviate site-specific skin conditions.
Editorial Notes
- Active ingredient(s): Imiquimod
- Listed indication(s): Actinic Keratosis, Superficial Basal Cell Carcinoma, Genital Warts
Available option
- 9 sachets - 5 %496-5-pct-12556